# Development of an Innovative Hemodialysis Method to Improve Dialytic Clearance of Protein-bound Uremic Toxins

> **NCT06595680** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Hospices Civils de Lyon** · enrollment: 12 (estimated)

## Conditions studied

- End Stage Renal Disease
- Chronic Hemolysis

## Interventions

- **DRUG:** Medialipide 20% perfusion
- **DRUG:** NaCl 0,9%
- **BIOLOGICAL:** Blood sample

## Key facts

- **NCT ID:** NCT06595680
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2027-01-22
- **Final completion:** 2027-01-22
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06595680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06595680, "Development of an Innovative Hemodialysis Method to Improve Dialytic Clearance of Protein-bound Uremic Toxins". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06595680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*